HIV-associated vascular diseases: structural and functional changes, clinical implications.
After more than two decades of AIDS epidemic, the spectrum of HIV-associated vascular diseases has mainly evolved from infectious and inflammatory vasculitides to premature atherosclerosis, its related contributing conditions (metabolic syndrome, dyslipidemia, insulin resistance syndrome) and complications (acute coronary and cerebrovascular syndromes). Today, as the AIDS epidemic further progresses worldwide and as the life expectancy of HIV-infected patients treated with effective antiviral regimens has dramatically increased, more than 10% of patients experience cardiovascular manifestations. The complex interplay between viral infection, inflammatory and cytokines pathways, protease inhibitors-induced hyperlipidemia and direct effects on endothelial cells has not, by far, been integrated in a single comprehensive pathogenesis network. However, recognition of its main components has resulted in a broader appreciation of cardiovascular risk and risk factors in HIV-infected/treated patients. Cardiovascular prevention is required in more than one half of HIV-infected/treated patients to achieve a reliable effectiveness of modern antiretroviral therapy. As the prognosis of HIV patients improves continuously, this rate is also likely to increase in the future.
Monsuez
Jean-Jacques
JJ
AP-HP, Hôpital René Muret, Policlinique médicale, Université Paris, Sevran, France. jean-jacques.monsuez@rmb.aphp.fr
Charniot
Jean-Christophe
JC
Escaut
Lelia
L
Teicher
Elina
E
Wyplosz
Benjamin
B
Couzigou
Carine
C
Vignat
Noëlle
N
Vittecoq
Daniel
D
D000818:Animals; D002318:Cardiovascular Diseases / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control* / Q000821:virology*; D015658:HIV Infections / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control* / Q000821:virology*; D015497:HIV-1 / Q000472:pathogenicity; D006801:Humans; D012307:Risk Factors